

Primary Brain Tumours Committee meeting 9

Date: 25th September 2017

Location: Royal college of Obstetrics and Gynaecology

Minutes: Confirmed

Committee members present:	
Tom Roques(Chair)	Present for items 1 – 19
Eileen Andrews	Present for items 1 – 19
Garth Cruickshank (Topic adviser)	Present for items 1 – 19
Sebastian Brandner	Present for items 1 – 19
Alison Cameron	Present for items 1 – 19
Catherine Derbyshire	Present for items 1 – 19
Sara Erridge	Present for items 1 – 19
Zoe Faulkner	Present for items 1 – 19
Sarah Jefferies	Present for items 1 – 19
Ingela Oberg	Present for items 1 – 19
Sara Robson	Present for items 1 – 19
Stuart Smith	Present for items 1 – 19
David Summers	Present for items 1 – 19
Isabella Robbins	Present for items 1 – 19

In attendance:		
Adam Storrow	NICE Business analyst (NICE)	Present for items 1–19
Alex Bates	Guideline lead (NGA)	Present for notes 1–19
Mia Schmidt Hansen	Systematic Reviewer (NGA)	Present for notes 1 – 10
Eva Gonzalez	Systematic reviewer (NGA)	Present for notes 11–19
Eleanor Howat	Project Manager (NGA)	Present for items 1 -10
Victoria Rowlands	Project Manager (NGA)	Present for notes 11 – 19

James Hawkins	Health Economist (NGA)	Present for notes 1 – 10
John Graham	Clinical Advisor (NGA)	Present for items 1- 10

Observers:	
Matthew Pretty johns (NGA)	(Present for notes 14)

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 9th Guideline Committee meeting on Primary Brain Tumours. The Committee members and attendees introduced themselves.

The Chair informed the Committee that no apologies had been received.

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Jeremy Rees	Consultant Neurologist	Advised father to buy shares in NovoCure, a company making Tumour treating Field technology (relevant to the treatment of glioma and brain metastases)	Personal, financial, specific	Following discussion with the chair, it was agreed to exclude this member from all discussion of the technology, and any discussions of technology that TTF might compete with (specifically all treatment for glioma and metastases). Consequently no recommendation on these topics

the date of the declaration will be conflicted.

The Chair and a senior member of the Developer's team noted that the following members would not participate in a part of the meeting:

Jeremy Rees will not be able to participate in future discussions regarding recommendations on TTF.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee accepted the minutes from the meeting.

4. Lay member forum

No comments were raised

5. Presentation – Results 1c) What is the optimal timing and extent of initial surgery for suspected low-grade glioma?

The guideline lead and the Chair took the committee through the Protocol for question 1c. The Committee made some slight changes and agreed the protocol.

6. Presentation- Results 2a) What is the optimal management (observation, surgery, radiotherapy, chemotherapy or combinations of these) for histologically proven low grade glioma?

Mia Schmidt Hansen took the committee through the review for question 2a. The Committee made some slight changes and agreed the protocol.

7. Draft Recs & LETR on 2a) What is the optimal management (observation, surgery, radiotherapy, chemotherapy or combinations of these) for histologically proven low grade glioma?

The Chair took the committee through drafting Recommendations for question 2a.

8. Health Economic results

James Hawkins took the committee through the final HE results. The committee reviewed the recommendations in light of the Health Economic analysis.

9. NICE Edits to Recommendations

The guideline lead and the Chair took the committee through the Editor's revisions to the short guideline.

Primary Brain Tumours Committee meeting

Date: 26th September 2017

Location: Royal college of Obstetrics and Gynaecology

Minutes: Confirmed

11. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the Guideline Committee meeting on Primary Brain Tumours. The Committee members and attendees introduced themselves.

The Chair informed the Committee that no apologies had been received.

12. Confirmation of matter under discussion, and declarations of interest

The Committee declared no new declarations of interest.

13. Lay member forum

No comments were raised in the lay member forum

14. Presentation – Results 1b) What is the most appropriate diagnostic imaging for patients being considered for focal treatment of their brain metastases?

Eva Gonzalez presented the results for 1b) What is the most appropriate diagnostic imaging for patients being considered for focal treatment of their brain metastases?

15. Drafting recs- 1b) What is the most appropriate diagnostic imaging for patients being considered for focal treatment of their brain metastases?

The committee drafted recs for question 1b.

16. Confirming Research recommendations

The committee confirmed the Research Recommendations and prioritised those for the short guideline.

17. Preference Sensitive decision points

The Chair and the Committee went over preference sensitive decision points in the short guideline.

18. Sign off 5e LETR

The chair and the committee finalised the LETR for review question 5e.

19. Sign off 6 LETR

The Chair and the Committee finalised the LETR for review question 6.

20.AOB & Close

The Chair asked the Committee whether there was any other business. The date of the next meeting was confirmed as the **24**th **& 25**th **October 2017**. The Chair closed the meeting.

Date of next meeting: 24th & 25th October 2017

Location of next meeting: RCOG, 27 Sussex Place Regents Park London